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Abstract 
Introduction: A blood transfusion in patients with thalassemia major is a important treatment 
base. Iron overload resulted from Long-term transfusion-related using iron chelators particularly 
by the deferoxamine can be reduced. deferoxamine transfusion is currently conducted at evening 
(6 nights on a week) and by the pump. Deferral of deferoxamine consumption caused iron 
overload and its symptoms. Furthermore, applying the other method which is easy to handle and 
reduce monthly deferoxamine consumption rate is essential. One of these methods which has 
been mentioned in references is simultaneous blood transfusion and deferoxamine. 
Methods: This was an experimental study that has been done on 34 thalasemic patiebts refered 
to Ardabil City hospital. In these patients, intravenous deferoxamine transfused with a three-way 
connection with blood transfution. The study duration was 6 month and all patients cheked in 
three and six month after treatment. 
Results: 15 patients were man (45.7%) and 19% were woman (54.3%). The mean age of Patients 
was 20.1 with 5.7standard deviation. Results showed that subcutaneous deferoxamine 
consumption rate and L1 three and six month after simultaneous blood transfusion and 
intravenous deferoxamine and also average rate of feritine three month after studying proportion 
to pre-studying had been reduced significantly. But ferritin reduction was not significant 
statistically six month after due to the arbitrary reduction of subcutaneous deferoxamine 
consumption and L1. Reduction rate of subcutaneous deferoxamine consumption in patients who 
had undergone splenectomy was more than other patients. Evaluating the impact of simultaneous 
intravenous deferoxamine and the blood transfusion in terms of age and gender was not 
meaningful statistically. 
Conclution: Simultaneous intravenous deferoxamine and the blood transfusion on thalassemia 
major cause significantly feritine reduction and subcotaneous deferoxamine consumption and L1 
that this method is applicable over patients who have undergone splenectomy. Therefore, It is 
recommended to use this method. 
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